Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Sep

Developing Antibody Drugs for Cardiovascular and Cerebrovascular Diseases: Translational Challenges and Design Priorities

The development of antibody therapeutics for cardiovascular and cerebrovascular diseases extends beyond the identification of biologically relevant targets. Successful translational progression hinges...

Read article >

Sep

How an Antibody Discovery Platform De-Risks First-in-Class Drug Programs

Developing a first-in-class therapeutic antibody involves significant scientific and commercial uncertainty. An advanced antibody discovery platform reduces these risks by improving target validation,...

Read article >

May

Another Global First! SGT003 Bispecific Antibody from Sungen Biomedical’s NexTreg™ Platform Accepted for IND by NMPA

On April 9, 2026, the Investigational New Drug (IND) application for SGT003, a novel foundational drug for tumor immunotherapy independently developed by Beijing Sungen Biomedical Technology Co., Ltd....

Read article >